28 February 2025
Swissmedic: 46 human medicinal products with new active substances authorised
Swissmedic has published its annual report on the authorisation of human medicinal products with new active substances. In 2024, Swissmedic authorised a total of 46 human medicinal products with new active substances for the Swiss market. This is an increase of 12% compared to the previous year.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Global regulators call for advancing alternatives to animal testing